NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Pfizer ‘s Q3 2024-25 Latest News: Revenue Falls by 0.37% YoY

January 31, 2025January 31, 2025| adminadmin| 0 Comments| 6:15 pm
[fetch_key]
Categories:

Share the post "Pfizer ‘s Q3 2024-25 Latest News: Revenue Falls by 0.37% YoY"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance.
🔹 Sales over the Year and quarter: The company’s sales declined by -0.37 % over the year, decrease in net sales/revenue by -8.6 %.
🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -2.37 %, Marginal decrease of -0.72% in other income during this quarter.
🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Pfizer Limited. Profit dropped by -1.83 % Year to Year, Pfizer Limited’s profitability dropped by -19.42 % Quarter to Quarter.
🔹 EPS over the Year and quarter: EPS increased by 2.84 % Year to Year. EPS decreased by -19.42 % in previous quarter. Analysis needed for shareholder value.

This analytical report on Pfizer Limited stretches beyond conventional financial metrics to include an in-depth exploration of the company’s long-term strategic plans and their alignment with current market conditions. It examines the sustainability of the company’s business model in light of emerging market trends and competitive pressures. The insight provided by seasoned industry analysts adds depth to the evaluation, offering predictions that help in assessing the company’s position and potential movements in its stock price. For investors, this report serves as a crucial tool in understanding the intrinsic value of the company and strategizing their investment moves accordingly.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 539.97 Cr Rs. 588.59 Cr Rs. 537.99 Cr -8.6 % -0.37 %
Expenses Rs. 387.42 Cr Rs. 399.34 Cr Rs. 392 Cr -1.84 % + 1.18 %
Operating Profit Rs. 152.55 Cr Rs. 189.25 Cr Rs. 145.99 Cr -22.86 % -4.3 %
OPM % 28.25 % 32.15 % 27.14 % -5.01 % -1.11 %
Other Income Rs. 43.8 Cr Rs. 43.07 Cr Rs. 42.76 Cr -0.72 % -2.37 %
Interest Rs. 2.86 Cr Rs. 2.1 Cr Rs. 1.51 Cr -28.1 % -47.2 %
Depreciation Rs. 17.55 Cr Rs. 14.99 Cr Rs. 14.8 Cr -1.27 % -15.67 %
Profit before tax Rs. 175.94 Cr Rs. 215.23 Cr Rs. 172.44 Cr -19.88 % -1.99 %
Tax % 26.12 % 26.43 % 26 % -0.43 % -0.12 %
Net Profit Rs. 129.98 Cr Rs. 158.35 Cr Rs. 127.6 Cr -19.42 % -1.83 %
EPS in Rs Rs. 27.12 Rs. 0 Rs. 27.89 0 % + 2.84 %


Today, we’re looking at Pfizer Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -0.37 %. However, it did see a marginal slip of -8.6 % from the previous quarter. Expenses decreased slightly by -1.84 % quarter-on-quarter, aligning with the annual rise of 1.18 %. Operating profit, while down -4.3 % compared to last year, faced a quarter-on-quarter dip of -22.86 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.11 %, but a shrinkage of -5.01 % sequentially. Other income fell by -0.72 % compared to the last quarter, despite an annual decline of -2.37 %. Interest expenses dropped significantly by -28.1 % from the previous quarter, yet the year-over-year decrease remains at a moderate -47.2 %. Depreciation costs fell by -1.27 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -15.67 %. Profit before tax declined annually by -1.99 % but saw a reduction from the preceding quarter by -19.88 %.
Tax expenses as a percentage of profits decreased slightly by -0.12 % compared to last year, with a more notable quarter-on-quarter decrease of -0.43 %. Net profit fell by -1.83 % year-on-year but witnessed a -19.42 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 2.84 % In summary, Pfizer Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 539.97 Cr Rs. 588.59 Cr Rs. 537.99 Cr -8.6 % -0.37 %
Expenses Rs. 387.42 Cr Rs. 399.34 Cr Rs. 392 Cr -1.84 % + 1.18 %
Operating Profit Rs. 152.55 Cr Rs. 189.25 Cr Rs. 145.99 Cr -22.86 % -4.3 %
Net Profit Rs. 129.98 Cr Rs. 158.35 Cr Rs. 127.6 Cr -19.42 % -1.83 %
EPS in Rs Rs. 27.12 Rs. 0 Rs. 27.89 0 % + 2.84 %


In reviewing Pfizer Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -0.37 % year-on-year, although there was a slight dip of -8.6 % from the previous quarter. Expenses rose by 1.18 % compared to the previous year, with a decrease of -1.84 % quarter-on-quarter. Operating Profit dropped by -4.3 % annually, and saw a -22.86 % decrease from the last quarter.
Net Profit showed yearly decrease of -1.83 %, and experienced a -19.42 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 2.84 % annually, In essence, while Pfizer Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

Join our telegram for more updates

Stay Updated with Our YouTube Videos

Related Post